U.S. Biosimilars Market Set For Rapid Growth Forecast 2020-2026| Key Players: F. Hoffmann-La Roche Ltd., AbbVie Inc., Merck & Co., Celltrion Inc., Coherus BioSciences, Inc., Teva Pharmaceutical Industries Ltd., Eli Lilly and Company

U.S. Biosimilars Market | 2021 Size, Growth, Share, Cap, Regional Analysis With Global Industry Forecast To 2027. The “U.S. Biosimilars Market” will gain momentum from the increasing government support to adopt biosimilars in the healthcare sectors. According to a report by Fortune Business Insights, titled, “Biosimilars: U.S. Market Analysis, Insights and Forecast, 2019-2026,” The U.S. Biosimilars Market is projected to reach US$ 17,696.0 Mn by 2026. The report provides valuable insights into the drivers influencing growth of the market. As per the report, The U.S. Biosimilars Market is anticipated to report an impressive CAGR of 54.7% during the forecast period. The report also states that the U.S. market was valued at US$ 436.1 Mn in 2018.

Key Players Operating in The U.S. Biosimilars Market Include:

Key players are involved in mergers and acquisition to strengthen their market position. Owing to increasing competition frequent innovations are taking place in the market. Some of the companies operating the industry are:

Hoffmann-La Roche Ltd.,
AbbVie Inc.,
Merck & Co.,
Celltrion Inc.,
Coherus BioSciences, Inc.,
Teva Pharmaceutical Industries Ltd.,
Eli Lilly and Company
Request a Sample Copy of the Research Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/u-s-biosimilars-market-100990

Increased Research and Development Initiatives to Drive the Market

Biosimilars are the copies of original products. Due to the high cost of pharmaceutical drugs, healthcare facilities are not accessible to people from every economical stratum. This is where biosimilars come to recuse. Being an identical copy, biosimilars help in treating chronic diseases like cancer and arthritis in an effective manner just as original medications do. The market is likely to grow during the forecast period because of an increasing demand from the masses. Also, a rise in research and development initiatives by prominent organizations have increased market opportunities. This has led to tough competition in the U.S. biosimilars market.

Out research methodology is robust and includes data triangulation based on bottom-up and top-down approaches. We validated the approximate market number with the help of primary research. Secondary research was conducted to find out detailed information about mergers & acquisitions, collaborations, joint ventures, and agreements. At the same time, we have derived significant information about the market dynamics associated with growth drivers, trends, and obstacles.

Autoimmune Diseases Segment Projected to Dominate the Market in the U.S.

The U.S. biosimilars market is classified into three segments, namely, by distribution channel, by disease indication, and by drug class. By distribution channel, the market is grouped into online pharmacy, hospital pharmacy, and retail pharmacy. In terms of disease indication, the market is divided into cancer and autoimmune diseases such as arthritis, neutropenia, psoriasis, and others. In 2018, the autoimmune diseases held a market share of 92.0%. The segment is anticipated to remain in the leading position the U.S. biosimilars market during the forecast period. Factors like increasing adoption of biosimilars, rise in the prevalence of autoimmune diseases, and availability of limited drugs are likely to boost the segment. The Centers of Disease Control and Prevention declared that approximately 26% adults are estimated to have arthritis by 2040.

The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing. The financial parameters which are assessed include the sales, profits and the overall revenue generated by the key players of Market. Furthermore, the report offers a detailed analysis and information as per U.S. Biosimilars Market Growth Analysis by manufacturers, market segments helping our readers to get a comprehensive overview of the global market. Several players are planning to focus on developing cost-effective products or services, aiming to maintain a strong foothold in the market.

Have Any Query? Ask Our Experts: https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/u-s-biosimilars-market-100990

Detailed Table of Content:



Introduction
1.1. Research Scope

1.2. Market Segmentation

1.3. Research Methodology

1.4. Definitions and Assumptions

Executive Summary
Market Dynamics
3.1. Market Drivers

3.2. Market Restraints

3.3. Market Opportunities

Key Insights
4.1 Prevalence of Key Disease Associated with the Scope - U.S., 2018

4.2 New Product Launch

4.3 Pipeline Analysis

4.4 Regulatory Scenario

4.5. Reimbursement Scenario

4.6. Patent Snapshot of Biologics

4.6 Key Industry Developments - Partnerships, Mergers & Acquisitions

U.S. Biosimilars Market Analysis, Insights and Forecast, 2015-2026
5.1. Key Findings / Summary

5.2. Market Analysis, Insights and Forecast – By Drug Class

5.2.1 Filgrastim & Pegfilgrastim

5.2.2 Monoclonal Antibodies

5.2.2 Others

5.3. Market Analysis, Insights and Forecast – By Disease Indication

5.3.1 Cancer

5.3.2 Autoimmune Diseases

5.3.2.1 Arthritis

5.3.2.2 Psoriasis

5.3.2.3 Neutropenia

5.3.2.4 Others

5.3.3 Others

5.4. Market Analysis, Insights and Forecast – By Distribution Channel

5.4.1 Hospital Pharmacy

5.4.2 Retail Pharmacy

5.4.3 Online Pharmacy

Competitive Analysis
6.1. Key Industry Developments

6.2. U.S. Market Share Analysis (2018)

6.3. Competition Dashboard

6.4. Comparative Analysis – Major Players

6.5. Company Profiles (Overview, Products & services, SWOT analysis, Recent developments, strategies, financials (based on availability))

About Us:

Fortune Business Insights™ offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.

At Fortune Business Insights™ we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.

Contact Us:
Fortune Business Insights™ Pvt. Ltd.
308, Supreme Headquarters,
Survey No. 36, Baner,
Pune-Bangalore Highway,
Pune - 411045, Maharashtra, India.

Phone:
US :+1 424 253 0390
UK : +44 2071 939123
APAC : +91 744 740 1245

Email: sales@fortunebusinessinsights.com

Linkedin | Twitter | BLogs

This release was published on openPR.